相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design and characterization of a surfactant-conjugated, long-acting, balanced GLP-1/glucagon receptor dual agonist
John J. Nestor et al.
PEPTIDE SCIENCE (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Centrality of Obesity in the Course of Severe COVID-19
Danfei Liu et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock et al.
LANCET (2021)
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study
Maria Alba et al.
CLINICAL OBESITY (2021)
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
Victoria E. R. Parker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Small molecule glucagon receptor antagonists: an updated patent review (2015-2019)
Chen Cheng et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships
Barry M. Popkin et al.
OBESITY REVIEWS (2020)
Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
Olof Eriksson et al.
SCIENTIFIC REPORTS (2020)
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
Joachim Tillner et al.
DIABETES OBESITY & METABOLISM (2019)
Obesity: global epidemiology and pathogenesis
Matthias Blueher
NATURE REVIEWS ENDOCRINOLOGY (2019)
Glucagon Receptor Signaling and Lipid Metabolism
Katrine D. Galsgaard et al.
FRONTIERS IN PHYSIOLOGY (2019)
Glucagon Regulation of Energy Expenditure
Maximilian Kleinert et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Philip D. Ambery et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Sofie Haedersdal et al.
MAYO CLINIC PROCEEDINGS (2018)
Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
R. Scott et al.
PEPTIDES (2018)
Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents
Teayoun Kim et al.
DIABETES (2018)
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Andreas Evers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes
Cristina B. Guzman et al.
DIABETES OBESITY & METABOLISM (2017)
GLP-1/glucagon receptor co-agonism for treatment of obesity
Miguel A. Sanchez-Garrido et al.
DIABETOLOGIA (2017)
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
V. Salem et al.
DIABETES OBESITY & METABOLISM (2016)
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
S. J. Henderson et al.
DIABETES OBESITY & METABOLISM (2016)
Bariatric Surgery and Long-term Durability of Weight Loss
Matthew L. Maciejewski et al.
JAMA SURGERY (2016)
Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma
Nicolai J. Wewer Albrechtsen et al.
EBIOMEDICINE (2016)
Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure
Jonatan Ising Bagger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PHYSIOLOGY OF PROGLUCAGON PEPTIDES: ROLE OF GLUCAGON AND GLP-1 IN HEALTH AND DISEASE
Darleen A. Sandoval et al.
PHYSIOLOGICAL REVIEWS (2015)
Action and therapeutic potential of oxyntomodulin
Alessandro Pocai
MOLECULAR METABOLISM (2014)
A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity
Elisabetta Bianchi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
Tricia M. Tan et al.
DIABETES (2013)
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Kirk M. Habegger et al.
DIABETES (2013)
Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala
J. A. Parker et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Differential effects of oxyntomodulin and GLP-1 on glucose metabolism
Xiaobing Du et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
Jonathan W. Day et al.
BIOPOLYMERS (2012)
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Philip E. Cryer
ENDOCRINOLOGY (2012)
The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
Jennifer R. Kosinski et al.
OBESITY (2012)
DPP-IV-resistant, long-acting oxyntomodulin derivatives
Alessia Santoprete et al.
JOURNAL OF PEPTIDE SCIENCE (2011)
(D-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions
Barry D. Kerr et al.
BIOCHEMICAL PHARMACOLOGY (2010)
The metabolic actions of glucagon revisited
Kirk M. Habegger et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Alessandro Pocai et al.
DIABETES (2009)
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Maralyn R. Druce et al.
ENDOCRINOLOGY (2009)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects - A double-blind, randomized, controlled trial
K Wynne et al.
DIABETES (2005)
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure
LL Baggio et al.
GASTROENTEROLOGY (2004)
Peripheral oxyntomodulin reduces food intake and body weight gain in rats
CL Dakin et al.
ENDOCRINOLOGY (2004)
Oxyntomodulin suppresses appetite and reduces food intake in humans
MA Cohen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats
CL Dakin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans
KF Petersen et al.
DIABETOLOGIA (2001)
分享论文
